摘要
目的探讨人乳头状瘤病毒16型(HPV16)、18型(HPV18)感染患者P53、Rb蛋白表达水平及与乳腺癌预后的关联性。方法回顾性分析2013年5月至2014年5月河北大学附属医院收治的90例乳腺癌患者的病理资料。所有患者均经HPV16/18 DNA检测阳性。统计乳腺癌组织和癌旁正常乳腺组织(距肿瘤边缘5 cm以外)P53、Rb阳性率。分析乳腺癌患者P53、Rb蛋白表达与临床病理特征的关系。随访6~60个月,分析P53、Rb蛋白表达与患者预后的相关性。结果乳腺癌组织P53、Rb阳性率分别为67.78%和52.22%,癌旁组织分别为31.11%和17.78%,差异均有统计学意义(P<0.05);P53阳性组与阴性组3年生存率、5年生存率差异均有统计学意义(P<0.05);Rb阳性组与阴性组3年生存率5年生存率差异无统计学意义(P>0.05)。结论HPV16/18型感染的P53表达阳性可能对乳腺癌患者预后产生不利影响,而Rb蛋白不是影响乳腺癌HPV感染患者预后的重要指标。
Objective To investigate the expression of P53 and Rb protein in human papillomavirus type 16(HPV16)and type 18(HPV18)infection and its correlation with breast cancer prognosis.Methods The pathological data of 90 patients with breast cancer admitted to our department from May 2013 to May 2014 were reviewed.All patients were positive with HPV16/18 DNA.The positive rates of P53 and Rb in breast cancer tissues and adjacent normal breast tissues(except 5 cm from the edge of the tumor)were counted.The relationship between P53 and Rb protein expression and clinicopathological features in breast cancer patients was analyzed.All patients were followed up for 6 to 60 months,and the correlation between P53 and Rb protein detection results and prognosis was analyzed.Results The positive rates of P53 and Rb in breast cancer tissues were 67.78%and 52.22%,respectively,and the adjacent tissues were 31.11%and 17.78%,respectively.The difference was statistically significant(P<0.05).The P53 positive group and the negative group survived for 3 years.There were significant differences in the rate of 5-year survival rate(P<0.05).There was no significant difference in the 5-year survival rate between the Rb-positive group and the negative group(P>0.05).Conclusion The positive expression of P53 in HPV16/18 infection may have an adverse effect on the prognosis of breast cancer patients.
作者
张鹏
桑梅香
陈晗
王晓春
刘现义
ZHANG Peng;SANG Mei-xiang;CHEN Han(Department of Breast Surgery,Affiliated Hospital of Hebei University,Baoding Hebei 071000,China;Department of Breast Surgery,Fourth Hospital of Hebei Medical University,Shijiazhuang Hebei 050031,China)
出处
《临床和实验医学杂志》
2019年第21期2270-2273,共4页
Journal of Clinical and Experimental Medicine
基金
国家自然科学基金项目(编号:81001178)
